心臟映射市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球心臟测绘市场规模达34亿美元，预计到2034年将以11.3%的复合年增长率成长，达到109亿美元。推动这一强劲增长的因素包括：心律不整患者数量的不断增长、测绘技术的快速创新以及人们对微创诊断程序日益增长的偏好。此外，电生理学领域投资的不断增长以及心血管医疗服务覆盖范围的不断扩大（尤其是在发展中医疗保健体系中），也正在加速市场的发展。随着世界各地的心臟科室纷纷采用即时视觉化和精确测绘的新技术，对心臟测绘工具的需求也迅速增长。医院和专科中心正大力推行精准引导治疗，以减少手术併发症并改善病患预后。

医疗现代化的推进，加上支持性报销框架和全球研究资金的增加，正在为成熟经济体和新兴经济体的心臟测绘技术塑造一个充满希望的未来。随着医院越来越重视精准医疗和个人化治疗方案，对即时心臟诊断的需求也日益增长。医疗保健系统正在投资尖端电生理实验室，各国政府也提供财政诱因，鼓励采用微创手术。同时，公共和私人资助机构正在将资源投入到旨在提高测绘准确性、降低手术风险以及开发人工智慧测绘平台的研究中。

2024年，标测导管市场占据74%的市占率。由于复杂心律不整病例的增多，以及微创电生理手术中对高清电解剖资料的需求，该市场保持强劲成长。高密度多电极导管系统正迅速成为业界黄金标准，因为它们使医生能够在短时间内收集数万个资料点，提供无与伦比的细节和准确性。这些标测解决方案有助于更有针对性、更有效率的消融，从而支持心房颤动和室性心动过速的识别和治疗。

接触式心臟标测领域在2024年创造了30亿美元的市场规模，预计到2034年将以11.6%的复合年增长率成长。这些系统透过与心臟组织保持持续接触，提供精确的电生理和解剖学读数，从而产生极其清晰的活化图和电压图。这种细节程度对于诊断和治疗通常需要精确定位的复杂心律不整尤其重要。由于其卓越的讯号质量，接触式标测工具在临床电生理学中广受欢迎。此外，能够即时追踪电讯号的自动化心臟标测系统使临床医生能够缩短手术时间，并透过更准确地检测问题组织来提高消融治疗的成功率。

2024年，美国心臟电生理市场规模达17亿美元。预计2025年至2034年，该市场的复合年增长率将达到10.6%。美国拥有高度发展的医疗基础设施，包括配备先进电生理系统的专科电生理实验室和心臟中心。领先的医院和学术研究中心定期采用先进的技术执行复杂的消融手术，以提高手术的准确性和安全性。良好的报销环境和广泛的电生理治疗保险覆盖范围，支持了高手术量，并促进了技术的更快普及。

塑造全球心臟测绘市场竞争格局的关键参与者包括美敦力、雅培实验室、强生、波士顿科学、乐普医疗、Kardium、微创医疗科学、APN Health 和 EnChannel Medical。这些公司正透过创新和策略措施积极促进市场发展。主要的心臟测绘公司正透过创新、临床合作和地理扩张等方式巩固其市场地位。这些公司正大力投资研发，以推出具有增强电极设计和更快讯号撷取能力的下一代导管。与顶级医院和学术机构的合作使先进的电解剖测绘平台能够进行真实世界的测试。许多参与者专注于自动化和 AI 整合软体，以改善消融过程中的资料分析。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 心血管疾病发生率高
    • 提高对心血管疾病治疗方案的认识
    • 政府对研究和资助的优惠政策
    • 产品技术进步
  • 产业陷阱与挑战
    • 心臟测绘系统成本高昂
    • 缺乏熟练且经验丰富的电生理学家
  • 市场机会
    • 映射系统在儿科心臟病学中的应用日益广泛
    • 3D电解剖映射的应用日益广泛
• 成长潜力分析
• 监管格局
  • 我们
  • 欧洲
• 技术格局
• 报销场景
• 差距分析
• 2024 年全球各产品定价分析
  • 地图系统
  • 测绘导管
• 波特的分析
• PESTEL分析
• 未来市场趋势
• 价值链分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
  • 按地区
• 竞争定位矩阵
• 主要市场参与者的竞争分析
• 关键进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 扩张计划

第五章：市场估计与预测：按产品，2021 - 2034 年

• 主要趋势
• 测绘导管
• 地图系统

第六章：市场估计与预测：按类型，2021 - 2034 年

• 主要趋势
• 接触式心臟测绘
• 非接触式心臟测绘

第七章：市场估计与预测：按适应症，2021 - 2034 年

• 主要趋势
• 心房震颤
• 心房扑动
• 室性心搏过速
• 其他适应症

第八章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 医院
• EP实验室
• 其他最终用途

第九章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Abbott Laboratories
• APN Health
• Boston Scientific
• EnChannel Medical
• Johnson & Johnson
• Kardium
• Lepu Medical
• Medtronic
• MicroPort Scientific

The Global Cardiac Mapping Market was valued at USD 3.4 billion in 2024 and is estimated to grow at a CAGR of 11.3% to reach USD 10.9 billion by 2034. This robust growth is being driven by a rising number of patients diagnosed with cardiac arrhythmias, rapid innovation in mapping technologies, and increased preference for minimally invasive diagnostic procedures. Alongside these factors, growing investments in electrophysiology and expanded access to cardiovascular care-particularly in developing healthcare systems-are accelerating market development. As cardiology departments worldwide adopt new techniques for real-time visualization and accurate mapping, the demand for cardiac mapping tools is rapidly increasing. Hospitals and specialty centers are emphasizing precision-guided treatments to reduce procedural complications and improve patient outcomes.

The push toward healthcare modernization, coupled with supportive reimbursement frameworks and an uptick in global research funding, is shaping a promising future for cardiac mapping technologies across both established and emerging economies. As hospitals increasingly prioritize precision medicine and personalized treatment plans, the demand for real-time cardiac diagnostics is accelerating. Healthcare systems are investing in cutting-edge electrophysiology labs, and governments are offering financial incentives to adopt minimally invasive procedures. At the same time, public and private funding bodies are channeling resources into research aimed at improving mapping accuracy, reducing procedural risks, and developing AI-powered mapping platforms.

In 2024, the mapping catheters segment held 74% share. This segment remains strong due to growing cases of complex heart rhythm disorders and the need for high-definition electroanatomical data during minimally invasive electrophysiological procedures. High-density and multi-electrode catheter systems are rapidly becoming the gold standard as they allow physicians to collect tens of thousands of data points within moments, offering unmatched detail and accuracy. These mapping solutions support the identification and treatment of atrial fibrillation and ventricular tachycardia by facilitating more targeted and efficient ablation.

The contact cardiac mapping segment generated USD 3 billion in 2024 and is forecasted to grow at a CAGR of 11.6% through 2034. These systems provide precise electrical and anatomical readings by maintaining continuous contact with cardiac tissue, producing exceptionally clear activation and voltage maps. This level of detail is particularly crucial in diagnosing and treating complex arrhythmias that often require pinpoint accuracy. Due to their superior signal quality, contact mapping tools are widely preferred in clinical electrophysiology. Furthermore, automated cardiac mapping systems capable of tracking electrical signals in real time are enabling clinicians to shorten procedures while improving success rates in ablation therapies by detecting problematic tissue with greater accuracy.

United States Cardiac Mapping Market generated USD 1.7 billion in 2024. The market is projected to grow at a CAGR of 10.6% from 2025 to 2034. The country benefits from a highly developed healthcare infrastructure, including specialized electrophysiology labs and cardiac centers outfitted with advanced mapping systems. Leading hospitals and academic research centers routinely perform complex ablation procedures with sophisticated technologies that enhance procedural accuracy and safety. A favorable reimbursement environment and wide insurance coverage for EP treatments support high procedure volumes and facilitate quicker technology adoption.

Key players shaping the competitive landscape in the Global Cardiac Mapping Market include Medtronic, Abbott Laboratories, Johnson & Johnson, Boston Scientific, Lepu Medical, Kardium, MicroPort Scientific, APN Health, and EnChannel Medical. These companies are actively contributing to market evolution through innovation and strategic initiatives. Major cardiac mapping firms are reinforcing their market standing through a combination of innovation, clinical partnerships, and geographic expansion. These companies are investing heavily in R&D to introduce next-generation catheters with enhanced electrode designs and faster signal acquisition capabilities. Collaborations with top-tier hospitals and academic institutions are enabling real-world testing of advanced electroanatomical mapping platforms. Many players are focusing on automation and AI-integrated software to improve data analysis during ablation procedures.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Type trends
  • 2.2.4 Indication trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 High incidence of cardiovascular diseases
    • 3.2.1.2 Rising awareness about the treatment options for cardiovascular diseases
    • 3.2.1.3 Favourable government policies for research and funding
    • 3.2.1.4 Technological advancements in the products
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of the cardiac mapping systems
    • 3.2.2.2 Lack of skilled and experienced electrophysiologists
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing use of mapping systems in pediatric cardiology
    • 3.2.3.2 Increasing adoption of 3D electroanatomical mapping
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Technology landscape
• 3.6 Reimbursement scenario
• 3.7 Gap analysis
• 3.8 Pricing analysis, by product, at global level, 2024
  • 3.8.1 Mapping systems
  • 3.8.2 Mapping catheters
• 3.9 Porter's analysis
• 3.10 PESTEL analysis
• 3.11 Future market trends
• 3.12 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
  • 4.3.1 By Region
    • 4.3.1.1 North America
    • 4.3.1.2 Europe
    • 4.3.1.3 Asia Pacific
    • 4.3.1.4 Latin America
    • 4.3.1.5 MEA
• 4.4 Competitive positioning matrix
• 4.5 Competitive analysis of major market players
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Mapping catheters
• 5.3 Mapping systems

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Contact cardiac mapping
• 6.3 Non-contact cardiac mapping

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Atrial fibrillation
• 7.3 Atrial flutter
• 7.4 Ventricular tachycardia
• 7.5 Other indications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 EP labs
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 APN Health
• 10.3 Boston Scientific
• 10.4 EnChannel Medical
• 10.5 Johnson & Johnson
• 10.6 Kardium
• 10.7 Lepu Medical
• 10.8 Medtronic
• 10.9 MicroPort Scientific